- Home
- ICON vs GLTO Comparison
ICON vs GLTO Comparison
Compare ICON & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- GLTO
- Stock Information
- Founded
- ICON 2023
- GLTO 2011
- Country
- ICON Greece
- GLTO Denmark
- Employees
- ICON N/A
- GLTO N/A
- Industry
- ICON
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- GLTO Health Care
- Exchange
- ICON Nasdaq
- GLTO Nasdaq
- Market Cap
- ICON 3.6M
- GLTO 4.0M
- IPO Year
- ICON 2024
- GLTO 2020
- Fundamental
- Price
- ICON $1.68
- GLTO $3.07
- Analyst Decision
- ICON Strong Buy
- GLTO Buy
- Analyst Count
- ICON 1
- GLTO 1
- Target Price
- ICON $4.50
- GLTO $10.00
- AVG Volume (30 Days)
- ICON 64.6K
- GLTO 82.7K
- Earning Date
- ICON 06-10-2025
- GLTO 05-08-2025
- Dividend Yield
- ICON 206.67%
- GLTO N/A
- EPS Growth
- ICON N/A
- GLTO N/A
- EPS
- ICON N/A
- GLTO N/A
- Revenue
- ICON $5,309,000.00
- GLTO N/A
- Revenue This Year
- ICON $76.76
- GLTO N/A
- Revenue Next Year
- ICON $30.43
- GLTO N/A
- P/E Ratio
- ICON N/A
- GLTO N/A
- Revenue Growth
- ICON 18.61
- GLTO N/A
- 52 Week Low
- ICON $1.60
- GLTO $2.01
- 52 Week High
- ICON $154.00
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- GLTO 53.39
- Support Level
- ICON N/A
- GLTO $2.92
- Resistance Level
- ICON N/A
- GLTO $3.38
- Average True Range (ATR)
- ICON 0.00
- GLTO 0.25
- MACD
- ICON 0.00
- GLTO 0.04
- Stochastic Oscillator
- ICON 0.00
- GLTO 57.53
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.